LLY vs JNJ vs ABBV
161 measures in 16 categories, one definition each, computed from filings and market data.
LLY77.7
Eli Lilly and Company
Healthcare · Drug Manufacturers - General
$1,257.03 +0.43%$1.18T mkt cap
Score DNA
JNJ64.2
Johnson & Johnson
Healthcare · Drug Manufacturers - General
$255.56 +0.90%$615.9B mkt cap
Score DNA
ABBV66.6
AbbVie Inc.
Healthcare · Drug Manufacturers - General
$285.42 +0.71%$504.4B mkt cap
Score DNA
Price, rebased to 100 three years ago
LLY JNJ ABBV · weekly adjusted closesSmart money 8Valuation 16Profitability (TTM) 12Returns on capital 11Growth 17Margin history & stability 7Liquidity (latest quarter) 7Leverage & solvency (latest quarter) 13Efficiency 11Cash flow & earnings quality 7Dividends & buybacks 9Scores & forensic checks 15Per share 7Size (TTM) 8Price performance 9Technicals 4
● marks the highest or lowest value where that direction is plainly stronger (margins, returns, coverage, leverage); multiples and yields are left unmarked. Bars show each stock's percentile within its own industry. n/a: the measure does not apply to lenders and insurers.
Smart money
8 measures| Measure | LLY | JNJ | ABBV |
|---|---|---|---|
| Insider open-market buys, 180d | 0 | 0 | 0 |
| Insider $ bought, 180d | — | — | — |
| Congress purchases, 180d | 5 | 8 | 1 |
| Last Congress purchase | 2026-09-04 | 2026-09-25 | 2026-05-01 |
| 13F net change in holders | +262 | +46 | +124 |
| ETFs adding shares, 30d | 2,145 | 1,797 | 1,804 |
| ETFs trimming, 30d | 1,798 | 1,601 | 1,578 |
| Net ETF funds, 30d | +347 | +196 | +226 |
Valuation
16 measures| Measure | LLY | JNJ | ABBV |
|---|---|---|---|
| P/E (TTM) | 44.3x
80th
|
29.3x
50th
|
79.9x
90th
|
| PEG (P/E ÷ 3-yr EPS CAGR) | 0.70
20th
|
1.45
60th
|
— |
| Price / sales | 14.9x
100th
|
6.3x
73rd
|
7.8x
91st
|
| Price / book | 34.9x
100th
|
7.2x
60th
|
— |
| Price / tangible book | 154.9x | — | — |
| Price / free cash flow | 59.0x
100th
|
32.9x
91st
|
26.4x
82nd
|
| Price / operating cash flow | 42.1x
100th
|
26.0x
91st
|
25.9x
82nd
|
| Enterprise value | $1.23T
100th
|
$644.2B
91st
|
$568.6B
82nd
|
| EV / sales | 15.4x
100th
|
6.6x
64th
|
8.8x
91st
|
| EV / EBITDA | 31.1x
91st
|
19.1x
55th
|
26.8x
73rd
|
| EV / EBIT | 32.4x
70th
|
24.8x
50th
|
42.7x
90th
|
| EV / free cash flow | 61.3x
100th
|
34.4x
91st
|
29.8x
82nd
|
| Earnings yield | 2.3%
27th
|
3.4%
55th
|
1.3%
18th
|
| FCF yield | 1.7%
0th
|
3.0%
9th
|
3.8%
18th
|
| Operating cash flow yield | 2.4%
0th
|
3.8%
9th
|
3.9%
18th
|
| Graham number (per share) | $159.66
100th
|
$82.19
67th
|
— |
Profitability (TTM)
12 measures| Measure | LLY | JNJ | ABBV |
|---|---|---|---|
| Gross margin | 83.4%
100th
|
68.8%
18th
|
71.5%
45th
|
| EBITDA margin | 49.6%
100th
|
34.4%
73rd
|
32.9%
55th
|
| Operating margin | 49.5%
100th
|
26.8%
64th
|
29.3%
73rd
|
| EBIT margin | 47.6%
100th
|
26.5%
64th
|
20.7%
45th
|
| Net margin | 33.5%
100th
|
21.5%
73rd
|
9.8%
45th
|
| NOPAT margin | 39.3%
100th
|
22.4%
64th
|
21.3%
55th
|
| FCF margin | 25.2%
55th
|
19.1%
27th
|
29.7%
82nd
|
| Operating cash flow margin | 35.3%
91st
|
24.2%
27th
|
30.3%
64th
|
| R&D / revenue | 18.3%
27th
|
15.4%
18th
|
15.1%
9th
|
| SG&A / revenue | 15.6%
9th
|
25.7%
73rd
|
22.8%
55th
|
| Stock comp / revenue | 0.8%
18th
|
1.4%
82nd
|
1.5%
100th
|
| Effective tax rate | 20.5%
55th
|
16.5%
27th
|
27.4%
82nd
|
Returns on capital
11 measures| Measure | LLY | JNJ | ABBV |
|---|---|---|---|
| ROE (on average equity) | 102.4%
100th
|
25.7%
60th
|
— |
| ROA | 22.0%
100th
|
10.7%
82nd
|
4.6%
45th
|
| ROIC | 39.2%
100th
|
19.4%
73rd
|
23.5%
91st
|
| ROCE | 40.1%
100th
|
17.8%
64th
|
14.2%
45th
|
| Return on tangible assets | 31.2%
100th
|
13.2%
64th
|
9.8%
45th
|
| Cash ROIC (OCF / invested capital) | 35.2%
91st
|
20.9%
36th
|
33.4%
82nd
|
| Gross profitability (GP / assets) | 47.0%
91st
|
33.1%
36th
|
34.1%
55th
|
| ROIC, 3-yr average | 29.7%
100th
|
24.8%
91st
|
10.8%
55th
|
| ROIC, 5-yr average | 34.4%
100th
|
24.2%
89th
|
— |
| ROE, 5-yr average | 66.8%
89th
|
29.6%
67th
|
— |
| Incremental ROIC | 66.5%
73rd
|
62.9%
64th
|
-202.7%
18th
|
Growth
17 measures| Measure | LLY | JNJ | ABBV |
|---|---|---|---|
| Revenue growth (TTM YoY) | 49.6%
100th
|
8.1%
64th
|
10.4%
91st
|
| Revenue growth (QoQ) | 16.0%
91st
|
5.2%
27th
|
13.3%
82nd
|
| Revenue CAGR, 3 yr | 39.2%
100th
|
4.4%
45th
|
4.7%
64th
|
| Revenue CAGR, 5 yr | 24.4%
91st
|
1.9%
18th
|
3.7%
55th
|
| Gross profit CAGR, 3 yr | 42.9%
100th
|
4.1%
36th
|
6.0%
55th
|
| Operating income CAGR, 3 yr | 68.1%
100th
|
5.8%
40th
|
2.8%
30th
|
| Net income growth (TTM YoY) | 93.5%
100th
|
-7.2%
40th
|
67.5%
80th
|
| Net income CAGR, 3 yr | 60.2%
100th
|
17.2%
70th
|
-10.1%
30th
|
| EPS growth (TTM YoY) | 94.9%
90th
|
-8.0%
40th
|
67.6%
70th
|
| EPS CAGR, 3 yr | 63.4%
100th
|
20.1%
70th
|
-10.1%
30th
|
| EPS CAGR, 5 yr | 35.0%
89th
|
5.3%
56th
|
-1.0%
44th
|
| FCF growth (TTM YoY) | — | 14.1%
80th
|
4.7%
50th
|
| FCF CAGR, 3 yr | 84.1%
100th
|
8.7%
45th
|
-8.3%
0th
|
| Operating cash flow CAGR, 3 yr | 65.8%
100th
|
7.5%
55th
|
-8.6%
0th
|
| Book value CAGR, 3 yr | 48.2%
100th
|
6.8%
56th
|
— |
| Dividend CAGR, 3 yr | 6.9%
80th
|
4.0%
70th
|
1.8%
50th
|
| Sustainable growth rate | 80.2%
100th
|
10.3%
44th
|
— |
Margin history & stability
7 measures| Measure | LLY | JNJ | ABBV |
|---|---|---|---|
| Gross margin, 3-yr average | 82.5%
100th
|
68.3%
36th
|
69.5%
45th
|
| Operating margin, 3-yr average | 42.7%
100th
|
26.3%
82nd
|
24.0%
55th
|
| Net margin, 3-yr average | 26.1%
82nd
|
30.1%
100th
|
8.7%
27th
|
| FCF margin, 3-yr average | 5.3%
0th
|
20.2%
36th
|
31.1%
91st
|
| Revenue stability (0-1) | 0.79
55th
|
0.39
18th
|
0.72
45th
|
| Earnings stability (0-1) | 0.69
100th
|
0.11
36th
|
0.30
55th
|
| Margin stability (0-1) | 0.95
64th
|
0.99
100th
|
0.93
45th
|
Liquidity (latest quarter)
7 measures| Measure | LLY | JNJ | ABBV |
|---|---|---|---|
| Cash & short-term investments | $8.9B
64th
|
$20.8B
100th
|
$6.6B
36th
|
| Net cash (− = net debt) | −$46.0B
27th
|
−$28.3B
64th
|
−$64.3B
0th
|
| Working capital | $16.9B
100th
|
$4.9B
55th
|
−$8.0B
0th
|
| Current ratio | 1.35
64th
|
1.09
27th
|
0.81
0th
|
| Quick ratio | 1.00
45th
|
0.81
27th
|
0.69
18th
|
| Cash ratio (cash + ST investments / current liabilities) | 0.19
18th
|
0.38
73rd
|
0.16
9th
|
| Defensive interval (days) | 430 days
82nd
|
361 days
73rd
|
274 days
45th
|
Leverage & solvency (latest quarter)
13 measures| Measure | LLY | JNJ | ABBV |
|---|---|---|---|
| Total debt | $54.9B
73rd
|
$49.0B
55th
|
$70.8B
100th
|
| Debt / equity | 1.62
60th
|
0.58
10th
|
— |
| Net debt / equity | 1.36
60th
|
0.33
0th
|
— |
| Debt / assets | 38.6%
36th
|
24.4%
0th
|
52.4%
73rd
|
| Debt / capital | 61.8%
60th
|
36.6%
10th
|
— |
| Debt / EBITDA | 1.39
0th
|
1.45
9th
|
3.34
55th
|
| Net debt / EBITDA | 1.16
9th
|
0.84
0th
|
3.03
55th
|
| Interest coverage (EBIT / interest) | 38.7x
100th
|
33.1x
91st
|
4.6x
36th
|
| Cash interest coverage | 28.7x
91st
|
30.2x
100th
|
6.7x
27th
|
| Debt payback (years of OCF) | 2.0 yrs
9th
|
2.1 yrs
18th
|
3.6 yrs
73rd
|
| Liabilities / assets | 76.2%
64th
|
57.7%
27th
|
104.3%
100th
|
| IS credit model rating | AA | AA | BB- |
| Implied credit spread (bps) | 80
0th
|
80
0th
|
550
91st
|
Efficiency
11 measures| Measure | LLY | JNJ | ABBV |
|---|---|---|---|
| Asset turnover | 0.66
100th
|
0.50
55th
|
0.47
36th
|
| Fixed asset turnover | 2.72
9th
|
4.15
45th
|
11.11
100th
|
| Inventory turnover | 0.9
0th
|
2.2
55th
|
3.6
91st
|
| Receivables turnover | 4.7
27th
|
5.3
73rd
|
4.9
45th
|
| Days sales outstanding | 78 days
73rd
|
69 days
27th
|
75 days
55th
|
| Days inventory outstanding | 398 days
100th
|
166 days
45th
|
100 days
9th
|
| Days payables outstanding | 146 days
73rd
|
109 days
36th
|
646 days
91st
|
| Cash conversion cycle (days) | 331 days
100th
|
126 days
55th
|
−471 days
0th
|
| Capex / revenue | 10.1%
100th
|
5.1%
60th
|
0.6%
0th
|
| Capex / depreciation | 4.82
100th
|
0.64
80th
|
0.05
0th
|
| Operating expense ratio | 31.6%
0th
|
39.8%
36th
|
36.9%
18th
|
Cash flow & earnings quality
7 measures| Measure | LLY | JNJ | ABBV |
|---|---|---|---|
| Operating cash flow / net income | 1.05
0th
|
1.13
10th
|
3.09
60th
|
| FCF / net income | 0.75
0th
|
0.89
10th
|
3.02
80th
|
| FCF / operating cash flow | 71.4%
20th
|
78.9%
30th
|
97.9%
100th
|
| Capex / operating cash flow | 28.6%
80th
|
21.1%
70th
|
2.1%
0th
|
| Accruals ratio | -1.1%
100th
|
-1.4%
91st
|
-9.7%
18th
|
| Sloan accruals ratio | 3.6%
100th
|
-1.6%
64th
|
-3.9%
36th
|
| Earnings quality score (0-1) | 1.00
30th
|
1.00
30th
|
0.75
0th
|
Scores & forensic checks
15 measures| Measure | LLY | JNJ | ABBV |
|---|---|---|---|
| IS score | 78
100th
|
64
45th
|
67
64th
|
| IS profitability | 100
100th
|
85
64th
|
62
45th
|
| IS growth | 88
100th
|
42
55th
|
76
91st
|
| IS value | 37
27th
|
42
45th
|
32
9th
|
| IS momentum | 94
100th
|
67
55th
|
91
91st
|
| IS risk (safety) | 100
91st
|
100
91st
|
50
9th
|
| IS quality | 84
82nd
|
84
91st
|
72
45th
|
| IS balance sheet | 54
82nd
|
69
100th
|
26
9th
|
| IS earnings quality | 67
36th
|
74
100th
|
59
18th
|
| IS cash flow | 62
27th
|
65
45th
|
77
82nd
|
| Piotroski F-score (0-9) | 9
91st
|
7
45th
|
7
45th
|
| Altman Z-score | 7.8
100th
|
5.3
91st
|
2.4
27th
|
| Beneish M-score | −2.01
100th
|
−2.49
91st
|
−2.82
27th
|
| Ohlson O-score | −8.38
36th
|
−9.00
9th
|
−7.50
73rd
|
| IS credit score | 86
91st
|
88
100th
|
40
9th
|
Size (TTM)
8 measures| Measure | LLY | JNJ | ABBV |
|---|---|---|---|
| Market cap | $1.18T
100th
|
$615.9B
91st
|
$504.4B
82nd
|
| Revenue | $79.7B
91st
|
$97.9B
100th
|
$64.4B
73rd
|
| EBITDA | $39.5B
100th
|
$33.7B
91st
|
$21.2B
73rd
|
| Net income | $26.7B
100th
|
$21.0B
91st
|
$6.3B
45th
|
| Free cash flow | $20.1B
100th
|
$18.7B
82nd
|
$19.1B
91st
|
| Total assets | $142.3B
82nd
|
$201.1B
91st
|
$135.1B
73rd
|
| Shareholders' equity | $33.9B
55th
|
$85.0B
91st
|
−$5.9B
0th
|
| Employees | 50,000
45th
|
141,700
100th
|
57,000
55th
|
Price performance
9 measures| Measure | LLY | JNJ | ABBV |
|---|---|---|---|
| 1 day | +0.4% | +0.9% | +0.7% |
| 1 week | +6.6% | −2.2% | +3.9% |
| 1 month | +9.1% | −5.4% | +8.1% |
| 3 months | +9.6% | +2.7% | +12.7% |
| 6 months | +35.6% | +9.1% | +37.0% |
| Year to date | +16.6% | +23.9% | +25.5% |
| 1 year | +52.3% | +34.5% | +26.2% |
| 3 years, cumulative | +111.0% | +75.4% | +107.1% |
| 5 years, cumulative | +459.6% | +79.7% | +201.3% |
Technicals
4 measures| Measure | LLY | JNJ | ABBV |
|---|---|---|---|
| RSI 14 | 68.6 | 43.8 | 71.1 |
| From 52-week high | −2.8% | −9.1% | −2.0% |
| From 52-week low | +60.6% | +39.3% | +49.6% |
| Beta | 0.45 | 0.23 | 0.28 |
InsiderStreet reports findings from filings and market data. A comparison is not a recommendation to buy or sell either stock.Every figure is computed in code · data as of 2026-10-17